8-K
Current Report
Eloxx Pharmaceuticals, Inc. Filed Acc 0001104659-20-025486
Exit or restructuring costs · Executive or director change · Regulation FD disclosure
- Item 2.05 Costs associated with exit or disposal activities
- Item 5.02 Departure or appointment of directors or officers
- Item 7.01 Regulation FD disclosure
From the SEC's structured data for this filing
Loading tm2011065d1_8k.htm…